Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMETA in MET-driven advanced papillary renal cell carcinoma
2021-000336-55Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in papillary renal cell carcinoma (PRCC) comparing Savolitinib + durvalumab, Sunitinib and Durvalumab monotherapy (3 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: active.
02
Drugs
savolitinibdurvalumabsunitinib
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on 2021-000336-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000336-55.